---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-23-000020"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:56:53.264526+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MoonLake Q3 cash $496M; positive Phase 2 data for sonelokimab in HS and PsA

## Summary
- Cash & equivalents $496.0M at Sept 30, 2023, expected to fund Phase 3 programs and regulatory filings.
- Positive full 24-week data from Phase 2 MIRA trial in hidradenitis suppurativa announced.
- Landmark 12-week data from Phase 2 ARGO trial in psoriatic arthritis presented.
- R&D expenses $7.6M in Q3 (down from $8.7M Q2); G&A expenses $5.4M (up from $4.5M).
- Phase 3 initiation targeted for 2024; End of Phase 2 FDA meeting in December 2023; 24-week ARGO data expected Q1 2024.

## SEC filing metadata
- accession: 0001821586-23-000020
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/0001821586-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/mnlk-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-23-000020
- JSON: https://secwatch.observer/filing/0001821586-23-000020.json
- Plain text: https://secwatch.observer/filing/0001821586-23-000020.txt

## Key facts
- Earnings Releases
  MoonLake Immunotherapeutics reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/0001821586-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.